dobutamine has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, Q; Liang, JF; Wu, LN; Xiao, H; Zheng, HX | 1 |
| Bakouboula, B; Chauvin, M; Douchet, MP; Morel, O | 1 |
2 other study(ies) available for dobutamine and Adenocarcinoma
| Article | Year |
|---|---|
Inhibitory effects of dobutamine on human gastric adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Dobutamine; Dose-Response Relationship, Drug; G1 Phase Cell Cycle Checkpoints; Humans; Neoplasm Invasiveness; Phosphoproteins; Phosphorylation; Stomach Neoplasms; Time Factors; Transcription Factors; YAP-Signaling Proteins | 2014 |
[Reversible cardiogenic shock under 5-fluorouracil treatment].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotonic Agents; Colorectal Neoplasms; Dobutamine; Dopamine; Fluorouracil; Humans; Male; Middle Aged; Shock, Cardiogenic | 2005 |